Since 2003 Trevor has founded and managed companies dedicated to developing and commercializing treatments for orphan-status diseases. He sold his...
In the last decade the bio-pharm industry has spent more than $1 trillion bringing 72 new cancer drugs to market. Patients and the healthcare systems around the world have spent many trillions paying for the drugs. According to a 2016 study …
Shocking as it seems, overall cancer survival has barely changed over the past decade. Despite the advancement of target and other therapies, the 70 cancer drugs approved in that time gave patients only an average 2.1 more months of life than older drugs, according to a study in J.A.M.A.
Read and learn about the most recent updates from us…
Neovia has global chemical-composition & use patents
USA, PCT, & China composition and use patents through 2038
Companies and Institutions Behind Our Success
ANU Pharmaceutical Company is an incubator company for the early-stage development of novel oncology compounds.
PUMC Pharmaceutical is a specialty pharmaceutical company.Since 1995, we have been working closely with the Peking Union Medical College (PUMC), the Chinese Ministry of Health and our international partners to meet the unmet medical needs of patients in China and around the world.
Prevail InfoWorks is a system integration and analytics software company with a unique combination of clinical expertise and engineering prowess. Providing best in Class Modular Technology for Improved Timelines and early observations in clinical trials. Prevail is managing Neovia’s first-in-human trial for NEV-801
The University of Iowa Pharmaceuticals has been manufacturing and testing pharmaceutical products in compliance with cGMPs for over 40 years. UIP provides contract pharmaceutical formulation development, clinical supply, and commercial manufacturing and analytical testing services for Neovia
Since 1973, Raymond has founded companies involved in health care, high technology, investment banking, real estate, and manufacturing across the...
Dr Yang is Senior Scientist and Scientific Director of an integrated citywide graduate medical education program in radiation oncology at...
Previously, Gerald worked in New York, London, San Francisco and Washington D.C. in various finance and strategy positions, including as...
Be the first to read
In its 2019 annual IND update to USA FDA, Neovia has reported progress for the continuing phase I(a) dose escalation...
Neovia presented preliminary phase I and potential “immunotherapy enhancement” data at the 2018 JP Morgan conference to an international audience...
Neovia presented data from a pilot study using its lead drug candidate NEV-801 showing synergistic effects with PD1 and CTLA4.
and Updates from